- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06187961
Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)
A Phase 2, Open-label, Single Arm Study of Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ze-yang Ding, M.D.
- Phone Number: +8613407156200
- Email: zyding@tjh.tjmu.edu.cn
Study Contact Backup
- Name: Han Gao
- Phone Number: +8617730117747
- Email: gh1023606887@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Ze-yang Ding, M.D.
- Phone Number: +8613407156200
- Email: zyding@tjh.tjmu.edu.cn
-
Contact:
- Han Gao
- Phone Number: +8617730117747
- Email: gh1023606887@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- hepatocellular carcinoma is proven on biopsy or confirmed by the presence of radiological hallmarks, according to the American Association for the Study of Liver Diseases or European Association for the Study of the Liver guidelines.
- Age ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Not suitable for radical surgery (including radical hepatic resection, liver transplantation or liver cancer ablation) after evaluation by the hepatobiliary tumor MDT expert group. Specifically, any of the following conditions are met:
- R0 resection is not feasible.
- In subjects without cirrhosis, the volume of normal liver parenchyma is less than 30% of the total volume, or in subjects with cirrhosis, the volume of normal liver parenchyma is less than 40% of the total volume, or ICG-R15>15%.
- BCLC stage B or C.
- No prior systemic anti-tumor treatment for hepatocellular carcinoma before the first dose.
- According to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V1.1), at least 1 measurable lesion, or a measurable lesion that has clearly progressed (based on RECIST V1.1 criteria) after local treatment.
Subjects with portal vein tumor thrombus (PVTT):
- Chen's group A and B, or Cheng's type I-III can be enrolled.
- Chen's group C, or Cheng's type IV (superior vena cava tumor thrombus) cannot be enrolled.
Subjects with hepatic vein tumor thrombus:
- VV1 and VV2 types can be enrolled.
- VV3 type, or Sakamoto type I (inferior vena cava tumor thrombus) can also be enrolled.
- Sakamoto type II (inferior vena cava tumor thrombus extending above the diaphragm), or Sakamoto type III (inferior vena cava tumor thrombus reaching the right atrium) cannot be enrolled.
- Subjects with oligometastases outside the liver can be enrolled: Oligometastases outside the liver are defined as up to three metastatic lesions in a maximum of two organs, with the largest diameter being 3cm.
- Child-Pugh score less than or equal to 7.
Adequate organ and bone marrow function, with laboratory test values meeting the following requirements within 7 days prior to inclusion (no blood components, cell growth factors, albumin, or other intravenous or subcutaneous corrective treatment drugs are allowed within 14 days prior to obtaining laboratory tests):
- Complete blood count: Absolute Neutrophil Count (ANC) ≥1.5×10^9/L; Platelet count (PLT) ≥75×10^9/L; Hemoglobin (HGB) ≥9.0 g/dL.
- Liver function: Total Bilirubin (TBIL) ≤2×Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤5×ULN; Serum albumin ≥28 g/L; Alkaline Phosphatase (ALP) ≤5×ULN.
- Kidney function: Serum Creatinine (Cr) ≤ 1.5×ULN or Clearance of Creatinine (CCr) ≥50mL/min (Cockcroft-Gault formula); Urinalysis shows proteinuria <2+; For subjects with baseline urinalysis showing proteinuria ≥2+, a 24-hour urine collection should be performed and 24-hour urinary protein quantification <1g.
- Coagulation function: International Normalized Ratio (INR) ≤2.3 or Prothrombin Time (PT) extension ≤6 seconds.
- Estimated life expectancy of ≥12 weeks.
- Female subjects of childbearing age or male subjects whose sexual partners are of childbearing age need to take effective contraceptive measures during the entire treatment period and for 6 months after the last medication.
- Signed written informed consent, and able to comply with the visit and related procedures stipulated in the protocol.
Exclusion Criteria:
- Histologically/cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc.
- History of hepatic encephalopathy or liver transplantation.
- Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Subjects with only radiologically detected minimal pleural effusion, ascites, or pericardial effusion without symptoms can be enrolled.
- Acute or chronic active hepatitis B or C infection, with hepatitis B virus (HBV) DNA >2000IU/ml or 10^4 copies/ml; hepatitis C virus (HCV) RNA >10^3 copies/ml; co-positive for hepatitis B surface antigen (HbsAg) and anti-HCV antibody. Subjects who meet the above criteria after antiviral treatment with nucleoside analogs can be enrolled.
- Presence of central nervous system metastases.
- History of esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months. Subjects assessed by the investigator to be at high risk of bleeding.
- Any life-threatening bleeding event within the past 3 months, including those requiring blood transfusion, surgery or local treatment, or continuous drug treatment.
- History of arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other serious thromboembolic events. Exceptions are made for thrombosis formation related to implanted venous infusion ports or catheters, or superficial vein thrombosis that has stabilized after routine anticoagulation treatment. Preventive use of low-dose low molecular weight heparin (such as enoxaparin 40 mg/day) is allowed.
- Continuous use of aspirin (>325 mg/day) or other known platelet function inhibitors such as clopidogrel or ticlopidine for 10 days within 2 weeks prior to the first dose.
- Uncontrolled hypertension, with systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy.
- Presence of any toxicity caused by previous treatment that has not recovered to grade 0 or 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0) before the first dose of study treatment (excluding alopecia, non-clinically significant and asymptomatic laboratory abnormalities).
- Symptomatic congestive heart failure (New York Heart Association class II-IV), left ventricular ejection fraction (LVEF) <50% as indicated by echocardiography.
- Symptomatic or poorly controlled arrhythmia. History of congenital long QT syndrome or corrected QTc >500 ms (calculated using the Fridericia formula) at screening.
- Severe bleeding tendency or coagulation disorder, or currently receiving thrombolytic therapy.
- History of gastrointestinal perforation and/or fistula, intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive intestinal resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea within the past 6 months.
- Received radiotherapy within 3 weeks prior to the first dose of study treatment. For patients who received radiotherapy more than 3 weeks prior to the first dose of study treatment, all of the following conditions must be met for inclusion: no current radiation-related toxicities, no need for corticosteroids, and exclusion of radiation pneumonitis, radiation hepatitis, radiation enteritis, etc.
- History or current diagnosis of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function, and other lung diseases.
- Active pulmonary tuberculosis, currently receiving anti-tuberculosis treatment, or received anti-tuberculosis treatment within 1 year prior to the first dose.
- Infection with human immunodeficiency virus (HIV) (HIV 1/2 antibody positive), known syphilis infection requiring treatment.
- Active or clinically uncontrolled severe infection. Severe infection within 4 weeks prior to the first dose, including but not limited to hospitalization for complications of infection, sepsis, or severe pneumonia.
- Active autoimmune disease requiring systemic treatment (such as disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency, etc.) is allowed. History of primary immunodeficiency. Patients with only autoantibody positivity need to be confirmed by the investigator whether there is an autoimmune disease.
- Use of immunosuppressive drugs within 4 weeks prior to the first dose, excluding intranasal, inhaled, or other local corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10mg/day prednisone or equivalent doses of other corticosteroids). Temporary use of corticosteroids for the treatment of dyspnea symptoms due to allergies or diseases such as asthma, chronic obstructive pulmonary disease, etc., is allowed.
- Received a live attenuated vaccine within 4 weeks prior to the first dose or planned to receive one during the study period.
- Major surgery (craniotomy, thoracotomy, or laparotomy) or unhealed wound, ulcer, or fracture within 4 weeks prior to the first dose. Minor surgical procedures or tissue biopsy within 7 days prior to the first dose, excluding venous puncture for the purpose of intravenous infusion, are excluded.
- Local treatment for hepatocellular carcinoma within 4 weeks prior to the first dose.
- Use of traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, etc., except for local use to control pleural effusion or ascites, etc.) within 2 weeks prior to the first dose.
- Other acute or chronic diseases, mental illnesses, or laboratory test abnormalities that may result in increased medical risk and/or uncertainty in survival assessment, or other conditions deemed by the investigator to be unsuitable for inclusion in the study.
- Diagnosis of other malignant tumors within 5 years prior to the first dose, excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or in situ carcinoma that has been radically resected. If other malignant tumors were diagnosed more than 5 years prior to the first dose, even if the liver lesions meet the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Study of Liver Diseases (AASLD), pathological or cytological diagnosis of the liver lesions must be confirmed to be hepatocellular carcinoma for inclusion.
- Previous treatment with any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy. Previous treatment with targeted therapy against VEGF and/or VEGFR, RAF, MEK, PDGFR, FGFR, etc.
- Known allergy to any component of oxaliplatin, 5-fluorouracil, calcium folinate, lenvatinib, or cadonilimab; or severe allergic reaction to other monoclonal antibodies in the past.
- Patients diagnosed with aortic dissection aneurysm, celiac trunk and superior mesenteric artery dissection aneurysm.
- Received treatment in other clinical trials within 4 weeks prior to the first dose.
- Pregnant or breastfeeding women.
- Patients with systemic multiple metastases, portal vein tumor thrombus involving the superior mesenteric vein, inferior vena cava tumor thrombus extending above the diaphragm or reaching the right atrium.
- Other acute or chronic diseases, mental illnesses, or laboratory test abnormalities that may result in the following outcomes: increased risk associated with study participation or study drug administration, or interference with the interpretation of study results, and other conditions that make the patient ineligible to participate in the study based on the judgement of the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAIC-len-cado
Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and cadonilimab as conversion therapy for downstaging.
|
administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
Other Names:
lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Amendable to Curative Surgical Interventions
Time Frame: from the date of first treatment to the date of last treatment, an average of 3 years
|
Number of patients amendable to curative surgical interventions defined as number of patients receiving curative surgical resection, transplantation, or ablation after successful down-sizing of tumor(s) by intervention.
|
from the date of first treatment to the date of last treatment, an average of 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: from the date of first treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years
|
measured from the date of first treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause (whichever occurs first).
Participants alive and without disease progression or lost to follow-up will be censored at the date of their last radiographic assessment.
|
from the date of first treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years
|
Overall survival (OS)
Time Frame: from the date of first treatment to the date of death from any cause, assessed up to 5 years
|
Overall survival (OS): measured from date of first treatment to the date of death from any cause.
Participants alive or lost to follow-up will be censored at the date of their last visit.
|
from the date of first treatment to the date of death from any cause, assessed up to 5 years
|
Incidence of Study-Related Adverse Events
Time Frame: from the date of first treatment to 90 days after last treatment, around 3 years and 90 days
|
Incidence, nature, and severity of adverse events graded according to the United States National Cancer Institute The Common Terminology Criteria for Adverse Events (NCI-CTCAE 5.0)
|
from the date of first treatment to 90 days after last treatment, around 3 years and 90 days
|
Quality of Life (QoL) after treatment
Time Frame: assessed form the date of first followup to radiographically documented progression or or death from any cause, up to 3 years
|
The life quality of every subject is assessed every 3 months during follow up according to the 45-item FACT-Hep questionnaire, which assesses generic HRQL concerns and disease-specific issues.
|
assessed form the date of first followup to radiographically documented progression or or death from any cause, up to 3 years
|
Time to progression (TTP)
Time Frame: from the date of first treatment to radiographically documented progression according to mRECIST, assessed up to 3 years
|
Time to progression (TTP): measured from the date of first treatment to radiographically documented progression according to mRECIST 1.1.
This does not include death from any cause.
|
from the date of first treatment to radiographically documented progression according to mRECIST, assessed up to 3 years
|
Time to intrahepatic tumor progression (TTITP)
Time Frame: from the date of first treatment to radiographically documented intrahepatic tumor progression according to mRECIST, assessed up to 3 years
|
Time to intrahepatic tumor progression (TTITP): measured from the date of first treatment to radiographically documented intrahepatic tumor progression according to mRECIST 1.1.
This does not include death from any cause.
|
from the date of first treatment to radiographically documented intrahepatic tumor progression according to mRECIST, assessed up to 3 years
|
Disease control rate (DCR)
Time Frame: from the date of first treatment to radiographically documented response according to mRECIST, assessed up to 3 years
|
Percentage of patients that had a CR, PR, or SD ≥ 6 months per mRECIST
|
from the date of first treatment to radiographically documented response according to mRECIST, assessed up to 3 years
|
overall response rate (ORR) measured by mRECIST criteria
Time Frame: from the date of first treatment to radiographically documented progression according to mRECIST, assessed up to 3 years
|
Complete response (CR): Disappearance of any intra-tumoral arterial enhancement in all target lesions; Partial response (PR): At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions; Stable disease (SD): Any cases that do not qualify for either partial response or progressive disease; Progressive disease (PD): An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started. ORR=CR+PR. |
from the date of first treatment to radiographically documented progression according to mRECIST, assessed up to 3 years
|
Pathological complete response (pCR)
Time Frame: from the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 5 years
|
Pathological response is assessed as the percentage of surface with non-viable cancer cells (represented by necrosis or fibrosis, the ultimate stage of necrosis) in relation to the total tumor area and will be equal to: 100% - viable cancer cells (%).
If there are multiple tumors, the mean percentage will be used.
|
from the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 5 years
|
Duration of response (DoR)
Time Frame: from the date of first documented evidence of CR or PR to first documented sign of PD or death from any cause according to mRECIST 1.1, assessed up to 3 years
|
Defined as the time from first documented evidence of CR or PR until the first documented sign of disease progression (PD) or death from any cause
|
from the date of first documented evidence of CR or PR to first documented sign of PD or death from any cause according to mRECIST 1.1, assessed up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Ze-yang Ding, M.D., Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Lenvatinib
Other Study ID Numbers
- 2023-S039
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Non-resectable
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Second Affiliated Hospital of Guangzhou Medical...Recruiting
-
Assistance Publique - Hôpitaux de ParisLaboratoire EISAINot yet recruitingHepatocellular Carcinoma Non-resectableFrance
-
Wan-Guang ZhangThe Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Jinan Military General HospitalRecruitingHepatocellular Carcinoma Non-resectableChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHepatocellular Carcinoma Non-ResectableChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
Clinical Trials on HAIC
-
Second Affiliated Hospital of Guangzhou Medical...First Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaboratorsRecruiting
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | Potentially ResectionChina
-
Shandong Cancer Hospital and InstituteRecruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Zhongda HospitalRecruiting
-
Peking University Cancer Hospital & InstituteUnknownHepatocellular Carcinoma | Transarterial Chemoembolization
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruitingIntrahepatic CholangiocarcinomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina